Chapter 6
Investment Trends
2023 U.S. Life Sciences Outlook
3 Minute Read
Looking for a PDF of this content?
Lab/R&D Investment Volume Declines but Pricing Remains Tight
Lab/R&D real estate investment sales fell back to relatively healthy historical levels in 2022. Total volume fell by 43% year-over-year to $14.4 billion. The biggest declines were in the San Francisco Bay Area (-62%) and Boston/Cambridge (-42%). Lesser declines occurred in San Diego (-17%) and the rest of the country (-27%).
Figure 28: U.S. Life Sciences Lab/R&D Property Sales (rolling four-quarter sum)
Source: MSCI, CBRE Research, February 2023.
While costlier debt markets affected life sciences asset pricing in 2022, the four-quarter moving average of lab/R&D cap rates stabilized in Q4 2022, mirroring a similar pattern in other sought-after property types such as industrial and multifamily. The spread between the average lab/R&D cap rate and that of all other office property types moved to a steep premium of nearly 83 basis points in Q4 2022 from a discount of more than 60 basis points in 2014.
Figure 29: U.S. Life Sciences Lab/R&D Cap Rates (rolling four-quarter average)
Source: MSCI, CBRE Research, February 2023.
Related Service
- Property Type
Life Sciences
We provide the life sciences industry solutions that maximize facility and investment performance across labs, manufacturing space and critical enviro...
Related Insights
- Article | Evolving Workforces
Integrated lab and extended reality solutions: the augmented future of lab asset management with CBRE
February 21, 2023 5 Minute Read
CBRE has pioneered the use of direct collaboration with original equipment manufacturers (OEMs) and on-site troubleshooting, driving forwards faster installatio...
- Chapter | Intelligent Investment
U.S. Real Estate Market Outlook 2023: Life Sciences
December 13, 2022 5 Minute Read
In 2023, Pandemic-fueled demand and capital infusion will give way to more normal market conditions, with better opportunities for occupiers.
- Brief | Intelligent Investment
Lab/R&D Space Market Remains Strong Despite H1 2022 Drop in Life Sciences Funding
August 3, 2022 3 Minute Read
After peaking in 2021, life sciences funding has plunged this year due to market uncertainty.
Contacts
Matthew Gardner
Americas Advisory Leader Life Sciences
Eric Stavriotis
Vice Chairman, Advisory & Transaction Services | Location Incentives
Insights in Your Inbox
Stay up to date on relevant trends and the latest research.